

*Review*

# Transcriptional regulation of the 5-HT<sub>1A</sub> receptor: implications for mental illness

Paul R. Albert\*

*Ottawa Hospital Research Institute (Neuroscience), University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada K1H 8M5*

The serotonin-1A (5-HT<sub>1A</sub>) receptor is an abundant post-synaptic 5-HT receptor (heteroreceptor) implicated in regulation of mood, emotion and stress responses and is the major somatodendritic autoreceptor that negatively regulates 5-HT neuronal activity. Based on animal models, an integrated model for opposing roles of pre- and post-synaptic 5-HT<sub>1A</sub> receptors in anxiety and depression phenotypes and response to antidepressants is proposed. Understanding differential transcriptional regulation of pre- versus post-synaptic 5-HT<sub>1A</sub> receptors could provide better tools for their selective regulation. This review examines the transcription factors that regulate brain region-specific basal and stress-induced expression of the 5-HT<sub>1A</sub> receptor gene (*Htr1a*). A functional polymorphism, rs6295 in the *Htr1a* promoter region, blocks the function of specific repressors Hes1, Hes5 and Deaf1, resulting in increased 5-HT<sub>1A</sub> autoreceptor expression in animal models and humans. Its association with altered 5-HT<sub>1A</sub> expression, depression, anxiety and antidepressant response are related to genotype frequency in different populations, sample homogeneity, disease outcome measures and severity. Preliminary evidence from gene × environment studies suggests the potential for synergistic interaction of stress-mediated repression of 5-HT<sub>1A</sub> heteroreceptors, and rs6295-induced upregulation of 5-HT<sub>1A</sub> autoreceptors. Targeted therapeutics to inhibit 5-HT<sub>1A</sub> autoreceptor expression and induce 5-HT<sub>1A</sub> heteroreceptor expression may ameliorate treatment of anxiety and major depression.

**Keywords:** serotonin; transcription; receptor; raphe; anxiety; depression

## 1. INTRODUCTION

The 5-HT<sub>1A</sub> receptor has been increasingly associated with alterations in mood and emotion and has opposing functions as a pre-synaptic somatodendritic autoreceptor and a post-synaptic heteroreceptor. The 5-HT<sub>1A</sub> autoreceptor mediates negative feedback inhibition on 5-HT neurons, while the 5-HT<sub>1A</sub> heteroreceptors mediate 5-HT actions on target neurons. We focus on the transcriptional mechanisms and polymorphic changes that regulate pre- versus post-synaptic 5-HT<sub>1A</sub> receptors, and how this differential regulation could be used to understand the etiology and improve the treatment of mental illnesses.

## 2. 5-HT<sub>1A</sub> AUTORECEPTORS AS BRAKES FOR 5-HT NEUROTRANSMISSION

The concept of the ‘autoreceptor’ as a receptor that regulates (usually inhibits) the release of its own neurotransmitter goes back to the 1960s, originally described by Carlsson and colleagues [1,2] for the dopamine system. The key observations that these receptors regulate release of their own neurotransmitters came from evidence that by inhibiting autoreceptors using pharmacological blockers such as haloperidol or

chlorpromazine, dopamine release and turnover was greatly augmented. Oppositely, agonists such as apomorphine suppressed basal dopamine release. These key observations were replicated in the noradrenergic and serotonergic systems, and now the concept of autoreceptors has been generalized to include a number of other systems, including histaminergic, glutaminergic, cholinergic and other major neurotransmitter systems [3].

For the serotonin (5-hydroxytryptamine, 5-HT) system, the presence of autoreceptors was indicated by evidence that non-selective agonist LSD or 5-HT itself reduced 5-HT release, while receptor antagonists like methiothepin increased 5-HT release [4]. Aghajanian’s group showed that autoregulation of firing was mediated by 5-HT receptors on the 5-HT neurons [5–7]. Using the selective agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), Hamon’s group identified the 5-HT<sub>1A</sub> receptor as the major autoreceptor on the cell body and dendrites of 5-HT neurons of the raphe nuclei [8–11]. The 5-HT<sub>1A</sub> autoreceptor was then shown to mediate 5-HT auto-inhibition [7,12]. A consistent observation has been that reduction or ablation of 5-HT<sub>1A</sub> autoreceptors leads to increased 5-HT neurotransmission [13–17], while over-expression of 5-HT<sub>1A</sub> autoreceptors reduces 5-HT neurotransmission [18–20]. While 5-HT<sub>1A</sub> antagonists do not greatly affect basal firing, they consistently reverse inhibition of firing by 5-HT<sub>1A</sub> agonist or specific reuptake inhibitor (SSRI) treatment, suggesting that the basal level of 5-HT under recording conditions may be insufficient to see effects. In 5-HT<sub>1A</sub> knockout

\*palbert@uottawa.ca

One contribution of 11 to a Theme Issue ‘The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms’.

animals, an elevated basal raphe firing may result from a chronic absence of 5-HT<sub>1A</sub> receptors. By contrast, the 5-HT<sub>1B</sub> subtype is the key autoreceptor on presynaptic 5-HT nerve terminals regulating 5-HT release [21,22]. Recently, targeting of the 5-HT<sub>1A</sub> autoreceptor to soma and dendrites has been shown to be mediated by interaction of the receptor C-terminal tail with Yif1B [23,24]. 5-HT<sub>1A</sub>-mediated autoinhibition involves 5-HT<sub>1A</sub>-induced hyperpolarization of raphe neurons that is mediated by coupling of pertussis toxin-sensitive Gi proteins to activation of inward-rectifying potassium (GIRK) channels [25–28], possibly GIRK2 channels [29], which are co-expressed with 5-HT<sub>1A</sub> receptors in raphe and post-synaptic regions [30]. In addition, 5-HT<sub>1A</sub> heteroreceptors mediate an indirect negative feedback pathway by inhibition of pyramidal cortical neurons that project to raphe 5-HT neurons [31]. Oppositely, 5-HT<sub>2A</sub> and 5-HT<sub>4</sub> receptors mediate positive feedback of 5-HT neurons via prefrontal cortex and hippocampus projections, respectively [31,32]. Together, the direct and indirect 5-HT<sub>1A</sub>-mediated feedback mechanisms negatively regulate the activity of the 5-HT system.

Release of 5-HT<sub>1A</sub>-mediated autoinhibition by receptor desensitization appears to play a key role in the efficacy of antidepressant treatments, especially 5-HT-SSRIs [13,33–35]. Acute treatment with SSRI leads to a local increase in 5-HT levels in the raphe nuclei [36,37], activating 5-HT<sub>1A</sub>-mediated autoinhibition to inhibit firing of 5-HT neurons. With chronic SSRI treatment, 5-HT<sub>1A</sub> autoreceptors (but not heteroreceptors) desensitize, restoring raphe firing to enhance 5-HT release. By contrast, sensitization of 5-HT<sub>1A</sub> heteroreceptors is observed following chronic antidepressant treatment, although the mechanisms involved remain unclear [38–43].

Activation of 5-HT<sub>1A</sub> heteroreceptors plays a prominent role in the antidepressant and neurogenic actions of SSRIs [44–46]. Several possible mechanisms have been implicated in 5-HT<sub>1A</sub> autoreceptor desensitization [42] including uncoupling from G-proteins [41,47–50], receptor internalization [51], G-protein inactivation [52] and reduction in 5-HT<sub>1A</sub> autoreceptors [38,53]. In addition, coupling to the GIRK is reduced upon chronic fluoxetine treatment [54], one mechanism that may disinhibit raphe firing and allow for enhanced 5-HT neurotransmission. However, these mechanisms of rapid desensitization do not account for the chronic treatment required for antidepressant effects, and are also rapidly reversible [51]. The above studies were done in normal animals, while in animal models of depression chronic antidepressant treatment leads to a downregulation of 5-HT<sub>1A</sub> autoreceptor RNA or binding sites in the raphe nuclei [55–57] (figure 1). Similarly, in human depression in elderly subjects a reduction in 5-HT<sub>1A</sub> autoreceptors was correlated with an increased response to SSRI treatment [58], while another study found that in patients treated with SSRIs, increased 5-HT<sub>1A</sub> autoreceptor availability correlated with more severe depression [59]. Thus, while rapid desensitization of 5-HT<sub>1A</sub> autoreceptors occurs, transcriptional downregulation of 5-HT<sub>1A</sub> autoreceptors may play a role in the long-term adaptive changes in response to chronic antidepressant treatment in

depressed subjects. Consistent with this, mice engineered to repress 5-HT<sub>1A</sub> autoreceptor expression in adults by only 30 per cent responded to chronic SSRI treatment within days, while wild-type mice failed to respond to a three-week treatment [19]. Since partial or complete repression of 5-HT<sub>1A</sub> autoreceptors enhances 5-HT neuronal activity and 5-HT release in target tissues [19,20,60], these studies clearly indicate the level of 5-HT<sub>1A</sub> autoreceptors serves as a gate for response to chronic SSRI treatment [61].

Alterations in 5-HT<sub>1A</sub> receptor expression result in anxiety- and depression-like behaviours in animal models. Knockout of the 5-HT<sub>1A</sub> receptor gene leads to increased anxiety behaviour in at least three different mouse strains [62–64]. Specific repression of 5-HT<sub>1A</sub> autoreceptors also increases anxiety, suggesting that their loss leads to increased activation of other post-synaptic 5-HT receptors [20]. Pharmacological blockade of 5-HT<sub>1A</sub> receptors in early post-natal development also elicits an anxiety phenotype [65], while early post-natal expression of forebrain 5-HT<sub>1A</sub> receptors rescues the anxiety phenotype of 5-HT<sub>1A</sub>-null mice [66]. Similarly, transient over-expression of 5-HT<sub>1A</sub> receptors reduces anxiety in mice [67]. Selective repression of 5-HT<sub>1A</sub> heteroreceptors leads to depression-like behaviour, consistent with a role for post-synaptic 5-HT<sub>1A</sub> receptors in depression [20]. In agreement with this, enhancement of 5-HT<sub>1A</sub>-Gi2 signalling reduced depression-like behaviours, presumably via 5-HT<sub>1A</sub> heteroreceptor signalling [46]. Furthermore, 5-HT<sub>1A</sub> heteroreceptors appear to be obligatory for response to chronic SSRI treatment since 5-HT<sub>1A</sub> knockout mice lack behavioural and neurogenic response to SSRI [68]. Thus, 5-HT<sub>1A</sub> heteroreceptors appear critical for both the development of the depression phenotype as well as the antidepressant response to chronic SSRI treatment. Conversely, the 5-HT<sub>1A</sub> autoreceptor negatively regulates the activity of 5-HT neurons, and restrains the development of the anxiety phenotype as well as reducing and delaying response to SSRI treatment in mouse models (figure 1).

### 3. TRANSCRIPTIONAL REGULATION OF 5-HT<sub>1A</sub> AUTORECEPTORS VERSUS HETERORECEPTORS

The earlier-mentioned results indicate the importance of the 5-HT<sub>1A</sub> autoreceptor as a brake for 5-HT neurotransmission *in vivo*, suggesting that regulators of the *Htr1a* gene might affect basal 5-HT neurotransmission and susceptibility to depression or anxiety disorders (figure 1). The *Htr1a* gene lacks introns in its coding region and is strongly expressed in specific brain regions, but almost not at all in non-neuronal tissues [69,70]. The *Htr1a* gene contains a GC-rich proximal promoter region containing DNA elements for several ubiquitous transcription factors, including Myc-associated zinc finger protein (MAZ), Sp1 and NFκB that drive its expression in all cell types examined [71–73]. By contrast, the *Htr1a* promoter also contains several Pet-1 sites recognized by the raphe-specific enhancer, Pet-1, which primarily enhances 5-HT<sub>1A</sub> autoreceptor expression [74]. Knockout of Pet-1 leads to reduced




Figure 1. Model for *Htr1a* dysregulation in human anxiety and depression. Shown is a model of differential *Htr1a* regulation in pre-synaptic raphe 5-HT neurons projecting to post-synaptic neurons in target tissues involved in mood and affect, such as prefrontal cortex, hippocampus, amygdala or hypothalamus. Pre-synaptic 5-HT<sub>1A</sub> autoreceptors (v) negatively regulate 5-HT firing neuronal activity and regulate the release of 5-HT (dots) and activation of post-synaptic 5-HT<sub>1A</sub> heteroreceptors. In normal subjects, the set point for raphe firing frequency is determined in part by the density of 5-HT<sub>1A</sub> autoreceptors that is restrained by repression at the rs6295 C(-1019) allele (bar); 5-HT<sub>1A</sub> heteroreceptors, especially in cortex appear to be increased by enhancer activity at the C(-1019) allele (arrow). In anxiety, the combination of genetic (rs6295 G(-1019) allele) and environmental (life stress) glucocorticoid-mediated repression of the 5-HT<sub>1A</sub> promoter leads to a stronger decrease in 5-HT<sub>1A</sub> heteroreceptors in glucocorticoid-sensitive tissues, such as hippocampus and prefrontal cortex, and to a lesser extent the raphe nucleus; anxiety subjects appear to compensate for the de-repression of 5-HT<sub>1A</sub> autoreceptors in the raphe. In depression, the combination of G(-1019) allele and stress promote reductions in post-synaptic 5-HT<sub>1A</sub> heteroreceptors; however, pre-synaptic 5-HT<sub>1A</sub> autoreceptors become upregulated due to the lack of Deaf1 repression at the G(-1019) allele, leading to reduced 5-HT release, and compensatory partial upregulation of 5-HT<sub>1A</sub> heteroreceptors. In this model, anti-depressants act mainly at heteroreceptors or other post-synaptic processes for anti-anxiety actions, while they also act to desensitize pre-synaptic sites to mediate antidepressant actions.

expression of 5-HT<sub>1A</sub> autoreceptors, as well as a general reduction in serotonergic differentiation markers [74,75]. Thus, Pet-1 is a key positive regulator of 5-HT<sub>1A</sub> autoreceptor expression.

To restrict *Htr1a* expression to neuronal cells, a series of repressor elements located upstream of the promoter coordinately silence the gene [73]. These include the RE-1 site for neural restrictive factor (REST/NRSF) [76] and a powerful dual repressor element that is regulated by a pair of conserved repressors, Freud-1/CC2D1A and Freud-2/CC2D1B [77–79]. Unlike REST, which silences neuronal genes mainly in non-neuronal cells, Freud-1 and Freud-2 also repress 5-HT<sub>1A</sub> expression in neuronal cells [76]. Reduction of Freud-1 or Freud-2 expression using antisense or siRNA increases expression of neuronal 5-HT<sub>1A</sub> receptors [78–81]. Together, these repressors silence the

*Htr1a* gene in non-neuronal cells, but reversibly regulate its expression in 5-HT<sub>1A</sub>-positive neuronal cells. In raphe cells, Freud-1 is co-expressed with 5-HT<sub>1A</sub> autoreceptors and represses the *Htr1a* gene, while in target regions both Freud-1 and Freud-2 are expressed, and they both repress *Htr1a* expression in non-serotonergic neuronal cells. Thus, Freud-1 is implicated in 5-HT<sub>1A</sub> autoreceptor expression, while both Freud-1 and Freud-2 regulate 5-HT<sub>1A</sub> heteroreceptor expression.

Another region implicated in 5-HT<sub>1A</sub> autoreceptor regulation is the C(-1019)G (rs6295) *Htr1a* promoter polymorphism located within a palindrome (inverted repeat) sequence that is recognized by transcription factors NUDR/Deaf1 and Hes proteins Hes1 and Hes5 [82,83]. In raphe cells, Deaf1 and Hes repress *Htr1a* and the polymorphic change prevents their binding and repression, upregulating 5-HT<sub>1A</sub> autoreceptor

expression. Hes1 and Hes5 are restricted to neuronal progenitors and silenced upon neuronal differentiation [84]. Knockout of Hes1 results in premature and expanded expression of midbrain 5-HT<sub>1A</sub> receptor RNA, suggesting a role for Hes1 to restrict 5-HT<sub>1A</sub> receptor expression to serotonergic neurons [83]. Recent results indicate that knockout of Deaf1 results in a 50 per cent increase in 5-HT<sub>1A</sub> autoreceptor expression in dorsal and medial raphe nuclei [85]. Thus, by disrupting repression both by Hes1/5 and by Deaf1, the G(-1019) allele is expected to increase 5-HT<sub>1A</sub> autoreceptor expression, reducing serotonergic activity and increasing the risk of depression (figure 1).

It is important to note that all of these transcriptional mechanisms interact to regulate 5-HT<sub>1A</sub> autoreceptor expression. For example, reduction in calcium levels by 5-HT<sub>1A</sub> autoreceptor signalling could relieve calcium-dependent inactivation of Freud-1 [78], leading to agonist-induced downregulation of *Htr1a* transcription. Oppositely, along with a trend for an increase in 5-HT<sub>1A</sub> RNA in raphe tissue from depressed versus control female subjects, REST and Deaf-1 RNA were also increased, suggesting a compensatory mechanism to normalize 5-HT<sub>1A</sub> autoreceptor expression [86]. Thus, transcriptional upregulation of the 5-HT<sub>1A</sub> autoreceptor in depression could be blunted by altered regulation of these key repressors in raphe cells.

Differential transcriptional regulation of 5-HT<sub>1A</sub> autoreceptors versus heteroreceptors is partly dictated by developmental and regional distribution of *Htr1a* transcriptional factors and alterations in regulators such as glucocorticoids. Thus, Pet-1 is raphe-specific, while Freud-2 is not detected in raphe cells and thus specifically regulates 5-HT<sub>1A</sub> heteroreceptors. Similarly, high- and low-affinity glucocorticoid receptors (mineralocorticoid receptor, MR, and glucocorticoid receptor, GR, respectively) are enriched in hippocampus compared with raphe and are critical for stress- or glucocorticoid-induced downregulation of hippocampal 5-HT<sub>1A</sub> receptors [40,71,87–92]. Consistent with the importance of negative regulation of 5-HT<sub>1A</sub> heteroreceptors by glucocorticoids, an inverse correlation between glucocorticoid levels and hippocampal and amygdala but not raphe 5-HT<sub>1A</sub> receptor levels is seen in anxiety disorder patients [93]. With elevated glucocorticoid conditions, such as in chronic mild stress or sleep deprivation [94,95], GR appears to repress 5-HT<sub>1A</sub> autoreceptors [96]. Glucocorticoids can also uncouple 5-HT<sub>1A</sub> autoreceptors by reducing GIRK2 RNA levels [29]. Paradoxically, over-expression of MR or GR in the mouse forebrain increases 5-HT<sub>1A</sub> heteroreceptor expression (possibly via suppression of glucocorticoids), which was associated with an anti-anxiety/anti-depressed phenotype and increased SSRI responsiveness, respectively [97,98]. Thus, chronic life stress may dysregulate the 5-HT system by reducing 5-HT<sub>1A</sub> heteroreceptor expression and increase susceptibility to mental illness (figure 1).

#### 4. IMPLICATIONS OF 5-HT<sub>1A</sub> AUTORECEPTOR DYSREGULATION FOR MENTAL ILLNESS

Several lines of evidence suggest that depression and anxiety disorders in humans are associated with alterations in 5-HT<sub>1A</sub> receptor expression. An increase in

5-HT<sub>1A</sub> autoreceptor expression has been reported in the rostral raphe region of post-mortem tissue from a depressed suicide victim compared with control subjects, but with reduced 5-HT<sub>1A</sub> autoreceptor levels in caudal raphe regions [99,100]. Positron emission tomography (PET) imaging studies in living depression patients using the 5-HT<sub>1A</sub> antagonist [<sup>11</sup>C]WAY100635 also show a prominent 50 per cent increase in 5-HT<sub>1A</sub> autoreceptors in antidepressant-free or naive depressed subjects [101–103], as well as a twofold increase in male bipolar depression patients [104]. An upregulation of 5-HT<sub>1A</sub> autoreceptors is likely to reduce serotonergic neurotransmission, as associated with human depression and suicide (figure 1).

With regard to 5-HT<sub>1A</sub> heteroreceptor expression, post-mortem studies have generally shown reduced 5-HT<sub>1A</sub> receptor expression in several regions of the frontal cortex of depressed suicide victims [105,106]. However, in depressed suicide tissue some cortical regions display any increase in 5-HT<sub>1A</sub> RNA, such as in the frontopolar cortex compared with a decrease in orbital frontal cortex suggesting that dysregulation of 5-HT<sub>1A</sub> heteroreceptors is region-specific [107,108]. Such region-specific changes in 5-HT<sub>1A</sub> receptor expression have not been observed in PET imaging studies, but rather global decreases or increases have been observed, which may reflect the limited spatial resolution of imaging studies [109]. In depression, decreases in 5-HT<sub>1A</sub> heteroreceptors are more pronounced than for autoreceptors [110–113], which do not change or increase. In panic disorder, there is a reduction in cortical 5-HT<sub>1A</sub> heteroreceptors that is normalized by treatment [114,115]. Similarly, in social anxiety disorder, reductions in 5-HT<sub>1A</sub> binding in amygdala and anterior cingulate cortex were most prominent, with some decrease in raphe [116]. Reduced cortical 5-HT<sub>1A</sub> receptors were correlated with anxiety behaviour in normal subjects [117,118]. These results are consistent with animal studies that indicate a key role for 5-HT<sub>1A</sub> heteroreceptors in anxiety-like behaviours in mice [20].

Discrepancies in PET imaging results from different groups may be accounted for by methodological differences in reference tissue [101,119], or by confounds such as limited resolution (e.g. for raphe sub-regions), medication status or ligand competition with receptor-bound 5-HT *in vivo*. With regard to ligand competition, since PET ligand [<sup>11</sup>C]WAY100635 is a high-affinity 5-HT<sub>1A</sub> antagonist, it detects total 5-HT<sub>1A</sub> receptors, not distinguishing between coupled or uncoupled receptors and is not readily displaced by 5-HT. Treatment of rats with fenfluramine to release synaptic 5-HT reduced [<sup>11</sup>C]WAY100635 only in hippocampus [120] but reduced [18F]MPPF (a lower-affinity antagonist) binding in several brain areas [121]. The recent development of a labelled 5-HT<sub>1A</sub> agonist may provide a sensitive measure of increase in functional 5-HT<sub>1A</sub> autoreceptors in depression [122].

Taken together, results from human and animal studies are consistent with a model in which anxiety disorder involves a reduction in 5-HT<sub>1A</sub> heteroreceptors in limbic areas, such as hippocampus, amygdala and prefrontal cortex, with a lesser decrease in 5-HT<sub>1A</sub> autoreceptors (figure 1). A reduction or



inactivation of 5-HT<sub>1A</sub> autoreceptors is correlated with increased amygdala activation typical of anxiety phenotypes and is thought to be due to increased 5-HT release [123]. On the other hand, depression appears to be driven by reduced 5-HT neurotransmission, in part due to an increase in pre-synaptic 5-HT<sub>1A</sub> autoreceptors which inhibits the release of 5-HT. As well, depression is associated with reduced levels of 5-HT<sub>1A</sub> heteroreceptors, particularly in the hippocampus and prefrontal cortex, that may be induced in part by chronic stress [124]. These results suggest that strategies that target preferentially post-synaptic 5-HT<sub>1A</sub> heteroreceptors may have greater effects in anxiety [125], while strategies that both augment 5-HT release and enhance post-synaptic 5-HT<sub>1A</sub> signalling would be more effective to treat depression. Consistent with this idea, chronic SSRI treatment of anxiety subjects selectively reduced post-synaptic 5-HT<sub>1A</sub> receptor levels in hippocampus and prefrontal cortex [126]. To date, 5-HT<sub>1A</sub> ligands, such as buspirone, have lacked selectivity, targeting both pre- and post-synaptic 5-HT<sub>1A</sub> receptors [127,128], and display limited efficacy for treatment of anxiety or depression. Because autoreceptors and heteroreceptors have opposing actions on serotonergic neurotransmission, these compounds are of limited benefit. Yet, in combination with SSRI, buspirone augments the antidepressant response due to preferential desensitization of 5-HT<sub>1A</sub> autoreceptors [129,130]. Recently, compounds with selectivity for post-synaptic receptors have been developed [131] that may demonstrate increased benefit for treatment of anxiety or depression.

It is important to emphasize that multiple mechanisms in addition to 5-HT<sub>1A</sub> autoreceptor levels regulate 5-HT neurotransmission and could contribute to depression and anxiety. For example, a reduction in TPH2 gene expression or activity [132], or reduced differentiation of 5-HT neurons as seen in *Pet-1*-deficient mice reduces 5-HT levels [74,75]. Hence, changes in 5-HT<sub>1A</sub> autoreceptor levels may be secondary to or enhanced by alterations in 5-HT levels. Furthermore, regional diversity of the raphe nuclei has been suggested, with a *Pet-1*-insensitive population of 5-HT neurons regulating anxiety behaviour [133]: differential regulation of 5-HT<sub>1A</sub> receptors within these populations may predispose to anxiety versus depression. Thus, certain populations of 5-HT neurons may display similar levels of 5-HT<sub>1A</sub> autoreceptors, while others may be affected by the rs6295 polymorphism, stress or other factors. The diversity of mechanisms regulating 5-HT neurotransmission is likely to underlie in part the heterogeneity of results in 5-HT<sub>1A</sub> receptor levels in depression. Nevertheless, therapeutic strategies that target 5-HT<sub>1A</sub> autoreceptors could be of benefit by resetting the level of 5-HT neurotransmission (figure 1).

## 5. ASSOCIATION OF rs6295 WITH ALTERED 5-HT<sub>1A</sub> RECEPTOR EXPRESSION IN HUMANS

As described earlier, the G(-1019) allele of rs6295 would be expected to cause an upregulation of 5-HT<sub>1A</sub> autoreceptor expression by preventing *Hes1* or *Deaf1* repression, but may induce selective reductions in post-synaptic 5-HT<sub>1A</sub> receptors in specific

brain regions due to blocking *Deaf1* enhancer activity [134]. Recent PET imaging studies in human-depressed patients show an association of rs6295 with an increase in raphe 5-HT<sub>1A</sub> binding potential. A significant association was observed in unmedicated or antidepressant-naïve depressed patients [102]. In this cohort, the rs6295 risk allele and genotype also associated with depression. In a replication study, the level of 5-HT<sub>1A</sub> receptor binding potential correlated with the genetic load, increasing from CC-CG-GG [101], which also correlated with reduced response to antidepressant treatment. In bipolar depression, the rs6295 genotype also tended to associate with increased raphe 5-HT<sub>1A</sub> binding [104]. A similar trend of increased 5-HT<sub>1A</sub> autoreceptor levels was seen using a different 5-HT<sub>1A</sub> ligand in two female depression patients with the GG genotype [135]. By contrast, in normal subjects, there was a trend for an association of increased 5-HT<sub>1A</sub> autoreceptor binding potential associated with the GG genotype, but this was not statistically significant [136]. The finding of a more robust increase in 5-HT<sub>1A</sub> autoreceptor levels with the GG genotype in depressed compared with normal subjects suggests that depressed subjects may not compensate efficiently for the dysregulation conferred by the G(-1019) allele.

Increase in 5-HT<sub>1A</sub> autoreceptors due to the rs6295 genotype may be augmented by a reduction in synaptic 5-HT release in depression and be reversed by SSRI antidepressants that increase synaptic 5-HT levels. Consistent with this, 5-HT<sub>1A</sub> autoreceptor levels negatively correlate with levels of the plasmalemmal 5-HT transporter (SERT) in PET studies [137,138], and in post-mortem studies [108,139]. Interestingly, increased 5-HT<sub>1A</sub> autoreceptor binding is associated with reduced response to antidepressants [102,140], which could reflect greater autoreceptor-mediated inhibition of 5-HT. Treatment of anxiety disorder patients with antidepressants appears to normalize the imbalance between increased 5-HT<sub>1A</sub> autoreceptor levels and decreased 5-HT<sub>1A</sub> heteroreceptors [141]. In addition, the level of 5-HT<sub>1A</sub> autoreceptors is altered by additional factors. For example, the level of 5-HT<sub>1A</sub> autoreceptor binding potential varies with the oestrous cycle in females [142], which may account for the increased predisposition of females to depression. Despite these variables and the small numbers of patients that can be studied by PET imaging, these data provide important evidence that the rs6295 polymorphism is functional in humans and leads to alterations in 5-HT<sub>1A</sub> receptor levels in depression.

## 6. ASSOCIATION STUDIES OF *Htr1a* POLYMORPHISMS IN DEPRESSION- AND ANXIETY-RELATED DISORDERS

Since the initial report of an association of rs6295 with major depression and completed suicide [82], several studies have replicated these results [143]. A meta-analysis confirmed the association of the G-allele of rs6295 with depression, and found an especially strong association in Asian depression [144]. This could be due to the much lower frequency of the G-allele in Asian populations (10–20%) compared with 40–50% in Caucasian subjects. Thus, a twofold

enrichment of the G-allele with depression may be observed in Asians, but a much smaller effect would be present in Caucasians. For example, in a study of a Caucasian Utah cohort with over 300 depressed and 300 control subjects, the G-allele was significantly enriched in depression by only 1.1-fold; the G/G genotype was 1.36-fold enriched [145]. Since these studies, several new association studies with the G-allele of rs6295 have been published for depression [101,146–150], negative emotionality [151], anxiety [150,152], eating disorder [153], bipolar depression [104,147], alcohol withdrawal symptoms [154] and suicide [155]. One study suggests that the G-allele may be most strongly associated with depression with co-morbid anxiety [150], consistent with the importance of dysregulated *Htr1a* expression in both disorders. In support of this, the G-allele was associated with reduced amygdala activation in normal subjects [156]. Interestingly, in panic disorder and depressed patients the G-allele associated with increased amygdala activation but reduced right prefrontal cortex activation [157,158], suggesting altered fear circuitry [124]. In addition, recent findings have associated the G(-1019) allele with reductions in cognitive functioning in mismatch, attentional and error monitoring paradigms [159–162]. Importantly, several studies of response to chronic SSRI treatment have found an association with reduced response of rs6295 alone or with other *Htr1a* polymorphisms [61,143,163–167]. Interestingly, the G-allele is associated with a reduced effect on negative symptoms of atypical antipsychotics that have partial agonist activity at 5-HT<sub>1A</sub> receptors [168,169]. Thus, the G-allele appears to both confer risk for affective disorders and resistance to antidepressant and antipsychotic treatments that target the 5-HT system.

Not all studies have identified the association of rs6295 with depression or psychological symptoms [170–172]. In these cases, the allele frequency was close to 50 per cent; hence, the expected effect size would be very small as argued already. In addition, stronger associations may be expected by use of ethnically homogenous populations [145], or examination of robust phenotypes, such as current depression or completed suicide rather than personality traits or suicidal thoughts, as done in the above-mentioned studies. A stronger association of rs6295 with current depression compared with depression traits is consistent with the idea that normal subjects may be able to compensate for 5-HT<sub>1A</sub> dysregulation in the presence of the G(-1019) allele, as suggested by PET imaging studies (see above). Most importantly, investigation of the association of rs6295 with a specific depression subtype (e.g. depression with co-morbid anxiety [150]) or specific endophenotypes (e.g. limbic activation, amygdala volume), appears to provide stronger associations in very small depression cohorts [124,157,173]. However, these studies need independent replication. The challenge remains to uncover reliable biomarkers and endophenotypes to distinguish different forms of depression and anxiety. By understanding the actions of specific functional polymorphisms, such as rs6295, it may be possible to sub-categorize different types of depression and rationally design optimal treatment strategies.

Based on studies of the 5-HT transporter long polymorphic repeat (5-HTTLPR), a well-studied promoter polymorphism [174], the role of early or late life stress in increasing vulnerability to depression or anxiety of the rs6295 polymorphism has also been examined. Unlike the 5-HTTLPR, early life stress did not appear to interact with the *Htr1a* genotype. The homozygous G(-1019) genotype was associated with panic disorder [152], but there was no interaction with early life stress. Similarly, no environment effect was seen in children with attention-deficit hyperactivity disorder (ADHD) for the association of the G-allele on emotional or anxiety behaviour [175]. Rather, recent stress may interact more strongly with rs6295 than early life stress in predisposing to depression [148]. Similarly, recent stress events, but not early life events, interacted with the *Htr1a* G-allele in susceptibility to complete suicide [155]. Similarly, bipolar depressed patients were more likely to be hospitalized after recent stress if they had the G/G *Htr1a* genotype [176]. In animal models, early life stress leads to region-specific alterations in 5-HT<sub>1A</sub> receptor levels [177,178] and appears to interact with late life stress to induce deficits in 5-HT<sub>1A</sub> receptor signalling [179]. Thus, stress-induced dysregulation of 5-HT<sub>1A</sub> receptor expression may be exacerbated by the presence of the G-allele, leading to increased predisposition to mental illness. Interestingly, the G-allele is associated with a blunted cortisol response to acute stress [180] and increased stress susceptibility [181], further suggesting a role for altered regulation of the 5-HT<sub>1A</sub> autoreceptor in impaired stress response in depressed patients [182]. In agreement with this, mice with an increase in 5-HT<sub>1A</sub> autoreceptors display impaired stress responses [19]. However, the specific interaction between 5-HT<sub>1A</sub> genotype and stress on 5-HT<sub>1A</sub> receptor expression and behavioural outcomes remains to be tested.

Genome-wide association studies have failed to confirm association with candidate genes [183], in part, because not all candidate gene polymorphisms were examined. However, specific genotype analysis for rs6295 identified an association of the G-allele with more severe depression symptoms and reduced response to citalopram in a subgroup of the STAR\*D sample [167]. In the larger sample, rs6295 was not examined, but other 5-HT<sub>1A</sub> polymorphisms were associated with antidepressant response. Interestingly, preliminary studies suggest that the C-allele may be associated with risk of illness for premenstrual dysphoria [184] or ADHD [185]. In a separate ADHD cohort, the G-allele was associated with decreased anxiety-fear disorders [175]. These findings need replication, but may suggest that hyperactivity of the 5-HT system due to fewer 5-HT<sub>1A</sub> autoreceptors could predispose to certain disorders such as ADHD.

## 7. CONCLUSION: A MODEL FOR 5-HT<sub>1A</sub> RECEPTOR DYSREGULATION IN AFFECTIVE DISORDERS

The results from studies in animal models and in human depression and anxiety suggest that altered 5-HT<sub>1A</sub> receptor expression leads to impaired serotonergic function and predisposes to depression and anxiety disorders

(figure 1). The G-allele of rs6295 5-HT<sub>1A</sub> promoter polymorphism or loss of Deaf1 function is associated with 5-HT<sub>1A</sub> autoreceptor upregulation *in vivo* [85,101], and inhibition of 5-HT neuronal firing frequency to reduce 5-HT release [19]. In addition, the C(-1019)G polymorphism reduces 5-HT<sub>1A</sub> heteroreceptor expression in a cell-specific manner [134], with loss of Deaf1 reducing 5-HT<sub>1A</sub> receptor levels in prefrontal cortex [85]. Other *Htr1a* polymorphisms in linkage disequilibrium with rs6295 have yet to be functionally characterized and may augment pre- or post-synaptic functions of the C(-1019)G change. Finally, stressful life environment, especially recent stress appears to enhance the susceptibility to depression or suicide that is conferred by the G(-1019) allele. Glucocorticoid-mediated downregulation of hippocampal 5-HT<sub>1A</sub> heteroreceptor expression could synergize with genotype-driven reductions. Presynaptically, glucocorticoid-induced repression may be particularly important in anxiety, whereas in depression, a blunted cortisol response and lack of stress sensitivity could reduce the effect of cortisol. In anxiety, 5-HT<sub>1A</sub> autoreceptor expression may be unaffected or reduced due to glucocorticoid-induced repression, while post-synaptic 5-HT<sub>1A</sub> heteroreceptors would be strongly reduced by both cortisol and rs6295 genotype. On the other hand, in depression, a G-allele-driven increase in 5-HT<sub>1A</sub> autoreceptor expression would mediate a reduction in 5-HT neuronal activity that predisposes to a depression phenotype [19,20].

Based on the different and sometimes opposing roles of pre- and post-synaptic 5-HT<sub>1A</sub> receptors in 5-HT regulation and behaviour, we propose that selective pharmacological manipulation of 5-HT<sub>1A</sub> autoreceptors or heteroreceptors might provide a way to improve the treatment of depression and anxiety. Potential approaches to selectively target the 5-HT<sub>1A</sub> autoreceptor could include targeting its greater autoreceptor reserve [186], Gi3-selective signalling [187,188], or desensitization with biased ligands [189]; targeting its differential regulation by transcription factors, such as Deaf1 or Freud1 [61]; or by enhancing the use of siRNA-based ligands to downregulate its expression [60]. Recently, intranasal administration of a chemical conjugate of an SSRI to 5-HT<sub>1A</sub> siRNA was shown to selectively reduce 5-HT<sub>1A</sub> autoreceptor expression and exert a rapid antidepressant effect, suggesting a novel clinical approach for antidepressant treatment [60]. A combination of selective 5-HT<sub>1A</sub> autoreceptor inactivation and SSRI treatment should lead to more effective and rapidly acting antidepressant treatment strategies.

P.R.A. was supported by operating funds from the Canadian Institutes of Health Research and equipment funding from the Heart and Stroke Centre for Stroke Recovery.

## REFERENCES

- Anden, N. E., Carlsson, A. & Haggendal, J. 1969 Adrenergic mechanisms. *Annu. Rev. Pharmacol.* **9**, 119–134. (doi:10.1146/annurev.pa.09.040169.001003)
- Carlsson, A. 1975 Dopamine autoreceptors. In *Chemical tools in catecholamine research* (eds O. Almgren, A. Carlsson & J. Engel), pp. 219–225. Amsterdam, The Netherlands: North-Holland.
- Starke, K., Gothert, M. & Kilbinger, H. 1989 Modulation of neurotransmitter release by presynaptic autoreceptors. *Physiol. Rev.* **69**, 864–989.
- Gothert, M. 1982 Modulation of serotonin release in the brain via presynaptic receptors. *Trends Pharmacol. Sci.* **3**, 437–440. (doi:10.1016/0165-6147(82)91222-6)
- Aghajanian, G. K. 1982 Regulation of serotonergic neuronal activity: autoreceptors and pacemaker potentials. *Adv. Biochem. Psychopharmacol.* **34**, 173–181.
- Sprouse, J. S. & Aghajanian, G. K. 1987 Electrophysiological responses of serotonergic dorsal raphe neurons to 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> agonists. *Synapse* **1**, 3–9. (doi:10.1002/syn.890010103)
- Liu, R. J., Lambe, E. K. & Aghajanian, G. K. 2005 Somatodendritic autoreceptor regulation of serotonergic neurons: dependence on L-tryptophan and tryptophan hydroxylase-activating kinases. *Eur. J. Neurosci.* **21**, 945–958. (doi:10.1111/j.1460-9568.2005.03930.x)
- Verge, D., Daval, G., Patey, A., Gozlan, H., el Mestikawy, S. & Hamon, M. 1985 Presynaptic 5-HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT<sub>1A</sub> subtype. *Eur. J. Pharmacol.* **113**, 463–464. (doi:10.1016/0014-2999(85)90099-8)
- Hall, M. D., el Mestikawy, S., Emerit, M. B., Pichat, L., Hamon, M. & Gozlan, H. 1985 [3H]8-hydroxy-2-(di-N-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain. *J. Neurochem.* **44**, 1685–1696. (doi:10.1111/j.1471-4159.1985.tb07155.x)
- Gozlan, H., El Mestikawy, S., Pichat, L., Glowinski, J. & Hamon, M. 1983 Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. *Nature* **305**, 140–142. (doi:10.1038/305140a0)
- Sotelo, C., Cholley, B., El Mestikawy, S., Gozlan, H. & Hamon, M. 1990 Direct immunohistochemical evidence of the existence of 5-HT<sub>1A</sub> autoreceptors on serotonergic neurons in the midbrain raphe nuclei. *Eur. J. Neurosci.* **2**, 1144–1154. (doi:10.1111/j.1460-9568.1990.tb00026.x)
- Penington, N. J. & Kelly, J. S. 1990 Serotonin receptor activation reduces calcium current in an acutely dissociated adult central neuron. *Neuron* **4**, 751–758. (doi:10.1016/0896-6273(90)90201-P)
- He, M., Sibille, E., Benjamin, D., Toth, M. & Shippenberg, T. 2001 Differential effects of 5-HT<sub>1A</sub> receptor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by *in vivo* microdialysis. *Brain Res.* **902**, 11–17. (doi:10.1016/S0006-8993(01)02271-5)
- Parsons, L. H., Kerr, T. M. & Tecott, L. H. 2001 5-HT(1A) receptor mutant mice exhibit enhanced tonic, stress-induced and fluoxetine-induced serotonergic neurotransmission. *J. Neurochem.* **77**, 607–617. (doi:10.1046/j.1471-4159.2001.00254.x)
- Richer, M., Hen, R. & Blier, P. 2002 Modification of serotonin neuron properties in mice lacking 5-HT<sub>1A</sub> receptors. *Eur. J. Pharmacol.* **435**, 195–203. (doi:10.1016/S0014-2999(01)01607-7)
- Haddjeri, N., Lavoie, N. & Blier, P. 2004 Electrophysiological evidence for the tonic activation of 5-HT(1A) autoreceptors in the rat dorsal raphe nucleus. *Neuropsychopharmacology* **29**, 1800–1806. (doi:10.1038/sj.npp.1300489)
- Bortolozzi, A., Amargos-Bosch, M., Toth, M., Artigas, F. & Adell, A. 2004 *In vivo* efflux of serotonin in the dorsal raphe nucleus of 5-HT<sub>1A</sub> receptor knockout mice. *J. Neurochem.* **88**, 1373–1379. (doi:10.1046/j.1471-4159.2003.02267.x)



- 18 Audero, E., Coppi, E., Mlinar, B., Rossetti, T., Caprioli, A., Banchaabouchi, M. A., Corradetti, R. & Gross, C. 2008 Sporadic autonomic dysregulation and death associated with excessive serotonin autoinhibition. *Science* **321**, 130–133. (doi:10.1126/science.1157871)
- 19 Richardson-Jones, J. W. *et al.* 2010 5-HT(1A) autoreceptor levels determine vulnerability to stress and response to antidepressants. *Neuron* **65**, 40–52. (doi:10.1016/j.neuron.2009.12.003)
- 20 Richardson-Jones, J. W. *et al.* 2011 Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. *J. Neurosci.* **31**, 6008–6018. (doi:10.1523/jneurosci.5836-10.2011)
- 21 Engel, G., Gothert, M., Hoyer, D., Schlicker, E. & Hillenbrand, K. 1986 Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT<sub>1B</sub> binding sites. *Naunyn Schmiedeberg's Arch. Pharmacol.* **332**, 1–7. (doi:10.1007/BF00633189)
- 22 Hery, F., Boulenguez, P., Semont, A., Hery, M., Becquet, D., Faudon, M., Deprez, P. & Fache, M. P. 1999 Identification and role of serotonin 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors in primary cultures of rat embryonic rostral raphe nucleus neurons. *J. Neurochem.* **72**, 1791–1801. (doi:10.1111/j.1471-4159.1990.tb02365.x)
- 23 Carrel, D., Masson, J., Al Awabdh, S., Capra, C. B., Lenkei, Z., Hamon, M., Emerit, M. B. & Darmon, M. 2008 Targeting of the 5-HT<sub>1A</sub> serotonin receptor to neuronal dendrites is mediated by Yif1B. *J. Neurosci.* **28**, 8063–8073. (doi:10.1523/JNEUROSCI.4487-07.2008)
- 24 Oh, E., Maejima, T., Liu, C., Deneris, E. S. & Herlitze, S. 2010 Substitution of 5-HT<sub>1A</sub> receptor signaling by a light-activated G protein-coupled receptor. *J. Biol. Chem.* **285**, 30 825–30 836. (doi:10.1074/jbc.M110.147298)
- 25 Pan, Z. Z., Wessendorf, M. W. & Williams, J. T. 1993 Modulation by serotonin of the neurons in rat nucleus raphe magnus *in vitro*. *Neuroscience* **54**, 421–429. (doi:10.1016/0306-4522(93)90263-F)
- 26 Pan, Z. Z., Colmers, W. F. & Williams, J. T. 1989 5-HT-mediated synaptic potentials in the dorsal raphe nucleus: interactions with excitatory amino acid and GABA neurotransmission. *J. Neurophysiol.* **62**, 481–486.
- 27 Williams, J. T., Colmers, W. F. & Pan, Z. Z. 1988 Voltage- and ligand-activated inwardly rectifying currents in dorsal raphe neurons *in vitro*. *J. Neurosci.* **8**, 3499–3506.
- 28 Innis, R. B. & Aghajanian, G. K. 1987 Pertussis toxin blocks 5-HT<sub>1A</sub> and GABAB receptor-mediated inhibition of serotonergic neurons. *Eur. J. Pharmacol.* **143**, 195–204. (doi:10.1016/0014-2999(87)90533-4)
- 29 Fairchild, G., Leitch, M. M. & Ingram, C. D. 2003 Acute and chronic effects of corticosterone on 5-HT<sub>1A</sub> receptor-mediated autoinhibition in the rat dorsal raphe nucleus. *Neuropharmacology* **45**, 925–934. (doi:10.1016/S0028-3908(03)00269-7)
- 30 Saenz del Burgo, L., Cortes, R., Mengod, G., Zarate, J., Echevarria, E. & Salles, J. 2008 Distribution and neurochemical characterization of neurons expressing GIRK channels in the rat brain. *J. Comp. Neurol.* **510**, 581–606. (doi:10.1002/cne.21810)
- 31 Celada, P., Puig, M., Amargos-Bosch, M., Adell, A. & Artigas, F. 2004 The therapeutic role of 5-HT(1A) and 5-HT(2A) receptors in depression. *J. Psychiatry Neurosci.* **29**, 252–265.
- 32 Lucas, G., Compan, V., Charnay, Y., Neve, R. L., Nestler, E. J., Bockaert, J., Barrot, M. & Debonnel, G. 2005 Frontocortical 5-HT<sub>4</sub> receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT<sub>4</sub> agonists. *Biol. Psychiatry* **57**, 918–925. (doi:10.1016/j.biopsych.2004.12.023)
- 33 Hjorth, S. & Auerbach, S. B. 1994 Further evidence for the importance of 5-HT<sub>1A</sub> autoreceptors in the action of selective serotonin reuptake inhibitors. *Eur. J. Pharmacol.* **260**, 251–255. (doi:10.1016/0014-2999(94)90346-8)
- 34 Hjorth, S., Bengtsson, H. J. & Milano, S. 1996 Raphe 5-HT<sub>1A</sub> autoreceptors, but not postsynaptic 5-HT<sub>1A</sub> receptors or beta-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine *in vivo*. *Eur. J. Pharmacol.* **316**, 43–47. (doi:10.1016/S0014-2999(96)00779-0)
- 35 Artigas, F., Romero, L., de Montigny, C. & Blier, P. 1996 Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT<sub>1A</sub> antagonists. *Trends Neurosci.* **19**, 378–383. (doi:10.1016/S0166-2236(96)10037-0)
- 36 Adell, A., Celada, P., Abellan, M. T. & Artigas, F. 2002 Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. *Brain Res. Rev.* **39**, 154–180. (doi:10.1016/S0165-0173(02)00182-0)
- 37 Giovacchini, G., Lang, L., Ma, Y., Herscovitch, P., Eckelman, W. C. & Carson, R. E. 2005 Differential effects of paroxetine on raphe and cortical 5-HT(1A) binding: a PET study in monkeys. *Neuroimage* **46**, 1128–1135. (doi:10.1016/j.neuroimage.2005.05.042)
- 38 Welner, S. A., De Montigny, C., Desroches, J., Desjardins, P. & Suranyi-Cadotte, B. E. 1989 Autoradiographic quantification of serotonin<sub>1A</sub> receptors in rat brain following antidepressant drug treatment. *Synapse* **4**, 347–352. (doi:10.1002/syn.890040410)
- 39 Haddjeri, N., Blier, P. & de Montigny, C. 1998 Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT<sub>1A</sub> receptors. *J. Neurosci.* **18**, 10 150–10 156.
- 40 Lopez, J. F., Chalmers, D. T., Little, K. Y. & Watson, S. J. 1998 A. E. Bennett Research Award. Regulation of serotonin<sub>1A</sub>, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. *Biol. Psychiatry* **43**, 547–573. (doi:10.1016/S0006-3223(97)00484-8)
- 41 Shen, C., Li, H. & Meller, E. 2002 Repeated treatment with antidepressants differentially alters 5-HT<sub>1A</sub> agonist-stimulated [35S]GTP gamma S binding in rat brain regions. *Neuropharmacology* **42**, 1031–1038. (doi:10.1016/S0028-3908(02)00064-3)
- 42 Hensler, J. G. 2003 Regulation of 5-HT<sub>1A</sub> receptor function in brain following agonist or antidepressant administration. *Life Sci.* **72**, 1665–1682. (doi:10.1016/S0024-3205(02)02482-7)
- 43 Zanoveli, J. M., Nogueira, R. L. & Zangrossi Jr, H. 2007 Enhanced reactivity of 5-HT<sub>1A</sub> receptors in the rat dorsal periaqueductal gray matter after chronic treatment with fluoxetine and sertraline: evidence from the elevated T-maze. *Neuropharmacology* **52**, 1188–1195. (doi:10.1016/j.neuropharm.2007.01.001)
- 44 Santarelli, L., Gobbi, G., Debs, P. C., Sibille, E. T., Blier, P., Hen, R. & Heath, M. J. 2001 Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. *Proc. Natl Acad. Sci. USA* **98**, 1912–1917. (doi:10.1073/pnas.041596398)
- 45 Greene, J., Banasr, M., Lee, B., Warner-Schmidt, J. & Duman, R. S. 2009 Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. *Neuropsychopharmacology* **34**, 2459–2468. (doi:10.1038/npp.2009.68)
- 46 Talbot, J. N., Jutkiewicz, E. M., Graves, S. M., Clemans, C. F., Nicol, M. R., Mortensen, R. M., Huang, X.,



- Neubig, R. R. & Traynor, J. R. 2010 RGS inhibition at G(alpha)i2 selectively potentiates 5-HT<sub>1A</sub>-mediated antidepressant effects. *Proc. Natl Acad. Sci. USA* **107**, 11 086–11 091. (doi:10.1073/pnas.1000003107)
- 47 Hensler, J. G. 2002 Differential regulation of 5-HT<sub>1A</sub> receptor-G protein interactions in brain following chronic antidepressant administration. *Neuropsychopharmacology* **26**, 565–573. (doi:10.1016/S0893-133X(01)00395-5)
- 48 Elena Castro, M., Diaz, A., del Olmo, E. & Pazos, A. 2003 Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT<sub>1A</sub> receptors in rat brain. *Neuropharmacology* **44**, 93–101. (doi:10.1016/S0028-3908(02)00340-4)
- 49 Rossi, D. V., Burke, T. F. & Hensler, J. G. 2008 Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram. *Eur. J. Pharmacol.* **583**, 103–107. (doi:10.1016/j.ejphar.2008.01.022)
- 50 Riad, M., Rbah, L., Verdurand, M., Aznavour, N., Zimmer, L. & Descarries, L. 2008 Unchanged density of 5-HT(1A) autoreceptors on the plasma membrane of nucleus raphe dorsalis neurons in rats chronically treated with fluoxetine. *Neuroscience* **151**, 692–700. (doi:10.1016/j.neuroscience.2007.11.024)
- 51 Riad, M., Zimmer, L., Rbah, L., Watkins, K. C., Hamon, M. & Descarries, L. 2004 Acute treatment with the antidepressant fluoxetine internalizes 5-HT<sub>1A</sub> autoreceptors and reduces the *in vivo* binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat. *J. Neurosci.* **24**, 5420–5426. (doi:10.1523/JNEUROSCI.0950-04.2004)
- 52 Beyer, C. E., Ghavami, A., Lin, Q., Sung, A., Rhodes, K. J., Dawson, L. A., Schechter, L. E. & Young, K. H. 2004 Regulators of G-protein signaling 4: modulation of 5-HT(1A)-mediated neurotransmitter release *in vivo*. *Brain Res.* **1022**, 214–220. (doi:10.1016/j.brainres.2004.06.073)
- 53 Fanelli, R. J. & McMonagle-Strucko, K. 1992 Alteration of 5-HT<sub>1A</sub> receptor binding sites following chronic treatment with ipsapirone measured by quantitative autoradiography. *Synapse* **12**, 75–81. (doi:10.1002/syn.890120109)
- 54 Cornelisse, L. N., van der Harst, J. E., Lodder, J. C., Baarendse, P. J., Timmerman, A., Mansvelder, H. D., Spruijt, B. M. & Brussaard, A. B. 2007 Reduced 5-HT<sub>1A</sub>- and GABAB-receptor function in dorsal raphe neurons upon chronic fluoxetine treatment of socially stressed rats. *J. Neurophysiol.* **98**, 196–204. (doi:10.1152/jn.00109.2007)
- 55 Yau, J. L., Olsson, T., Noble, J. & Seckl, J. R. 1999 Serotonin receptor subtype gene expression in the hippocampus of aged rats following chronic amitriptyline treatment. *Brain Res. Mol. Brain Res.* **70**, 282–287. (doi:10.1016/S0169-328X(99)00172-2)
- 56 Le Poul, E., Boni, C., Hanoun, N., Laporte, A. M., Laaris, N., Chauveau, J., Hamon, M. & Lanfumey, L. 2000 Differential adaptation of brain 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors and 5-HT transporter in rats treated chronically with fluoxetine. *Neuropharmacology* **39**, 110–122. (doi:10.1016/S0028-3908(99)00088-X)
- 57 Casanovas, J. M., Vilario, M. T., Mengod, G. & Artigas, F. 1999 Differential regulation of somatodendritic serotonin 5-HT<sub>1A</sub> receptors by 2-week treatments with the selective agonists alnespirone (S-20499) and 8-hydroxy-2-(di-N-propylamino)tetralin: microdialysis and autoradiographic studies in rat brain. *J. Neurochem.* **72**, 262–272. (doi:10.1046/j.1471-4159.1999.0720262.x)
- 58 Meltzer, C. C. *et al.* 2004 Serotonin 1A receptor binding and treatment response in late-life depression. *Neuropsychopharmacology* **29**, 2258–2265. (doi:10.1038/sj.npp.1300556)
- 59 Rabiner, E. A., Bhagwagar, Z., Gunn, R. N., Cowen, P. J. & Grasby, P. M. 2004 Preferential 5-HT(1A) autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression? *Neuropsychopharmacology* **29**, 1688–1698. (doi:10.1038/sj.npp.1300472)
- 60 Bortolozzi, A. *et al.* 2011 Selective siRNA-mediated suppression of 5-HT(1A) autoreceptors evokes strong anti-depressant-like effects. *Mol. Psychiatry* **17**, 612–623. (doi:10.1038/mp.2011.92)
- 61 Albert, P. R. & Francois, B. L. 2010 Modifying 5-HT<sub>1A</sub> receptor gene expression as a new target for antidepressant therapy. *Front Neurosci.* **4**, 35. (doi:10.3389/fnins.2010.00035)
- 62 Parks, C. L., Robinson, P. S., Sibille, E., Shenk, T. & Toth, M. 1998 Increased anxiety of mice lacking the serotonin1A receptor. *Proc. Natl Acad. Sci. USA* **95**, 10 734–10 739. (doi:10.1073/pnas.95.18.10734)
- 63 Heisler, L. K., Chu, H. M., Brennan, T. J., Danao, J. A., Bajwa, P., Parsons, L. H. & Tecott, L. H. 1998 Elevated anxiety and antidepressant-like responses in serotonin 5-HT<sub>1A</sub> receptor mutant mice. *Proc. Natl Acad. Sci. USA* **95**, 15 049–15 054. (doi:10.1073/pnas.95.25.15049)
- 64 Ramboz, S., Oosting, R., Amara, D. A., Kung, H. F., Blier, P., Mendelsohn, M., Mann, J. J., Brunner, D. & Hen, R. 1998 Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. *Proc. Natl Acad. Sci. USA* **95**, 14 476–14 481. (doi:10.1073/pnas.95.24.14476)
- 65 Lo Iacono, L. & Gross, C. 2008 Alpha-Ca<sup>2+</sup>/calmodulin-dependent protein kinase II contributes to the developmental programming of anxiety in serotonin receptor 1A knock-out mice. *J. Neurosci.* **28**, 6250–6257. (doi:10.1523/JNEUROSCI.5219-07.2008)
- 66 Gross, C., Zhuang, X., Stark, K., Ramboz, S., Oosting, R., Kirby, L., Santarelli, L., Beck, S. & Hen, R. 2002 Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. *Nature* **416**, 396–400. (doi:10.1038/416396a)
- 67 Kusserow, H. *et al.* 2004 Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors. *Brain Res. Mol. Brain Res.* **129**, 104–116. (doi:10.1016/j.molbrainres.2004.06.028)
- 68 Santarelli, L. *et al.* 2003 Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* **301**, 805–809. (doi:10.1126/science.1083328)
- 69 Albert, P. R., Zhou, Q. Y., Van Tol, H. H., Bunzow, J. R. & Civelli, O. 1990 Cloning, functional expression, and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. *J. Biol. Chem.* **265**, 5825–5832.
- 70 Hall, H. *et al.* 1997 Autoradiographic localization of 5-HT<sub>1A</sub> receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. *Brain Res.* **745**, 96–108. (doi:10.1016/S0006-8993(96)01131-6)
- 71 Wissink, S., Meijer, O., Pearce, D., van der Burg, B. & van der Saag, P. T. 2000 Regulation of the rat serotonin-1A receptor gene by corticosteroids. *J. Biol. Chem.* **275**, 1321–1326. (doi:10.1074/jbc.275.2.1321)
- 72 Parks, C. L. & Shenk, T. 1996 The serotonin 1a receptor gene contains a TATA-less promoter that responds to MAZ and Sp1. *J. Biol. Chem.* **271**, 4417–4430. (doi:10.1074/jbc.271.8.4417)
- 73 Albert, P. R., Le Francois, B. & Millar, A. M. 2011 Transcriptional dysregulation of 5-HT<sub>1A</sub> autoreceptors in mental illness. *Mol Brain* **4**, 21. (doi:10.1186/1756-6606-4-21)

- 74 Jacobsen, K. X., Czesak, M., Deria, M., Le Francois, B. & Albert, P. R. 2011 Region-specific regulation of 5-HT<sub>1A</sub> receptor expression by Pet-1-dependent mechanisms *in vivo*. *J. Neurochem.* **116**, 1066–1076. (doi:10.1111/j.1471-4159.2010.07161.x)
- 75 Liu, C., Maejima, T., Wyler, S. C., Casadesus, G., Herlitze, S. & Deneris, E. S. 2010 Pet-1 is required across different stages of life to regulate serotonergic function. *Nat. Neurosci.* **13**, 1190–1198. (doi:10.1038/nn.2623)
- 76 Lemonde, S., Rogaeva, A. & Albert, P. R. 2004 Cell type-dependent recruitment of trichostatin A-sensitive repression of the human 5-HT<sub>1A</sub> receptor gene. *J. Neurochem.* **88**, 857–868. (doi:10.1046/j.1471-4159.2003.02223.x)
- 77 Ou, X. M., Jafar-Nejad, H., Storrington, J. M., Meng, J. H., Lemonde, S. & Albert, P. R. 2000 Novel dual repressor elements for neuronal cell-specific transcription of the rat 5-HT<sub>1A</sub> receptor gene. *J. Biol. Chem.* **275**, 8161–8168. (doi:10.1074/jbc.275.11.8161)
- 78 Ou, X. M., Lemonde, S., Jafar-Nejad, H., Bown, C. D., Goto, A., Rogaeva, A. & Albert, P. R. 2003 Freud-1: a novel calcium-regulated repressor of the 5-HT<sub>1A</sub> receptor gene. *J. Neurosci.* **23**, 7415–7425.
- 79 Hadjighassem, M. R., Austin, M. C., Szewczyk, B., Daigle, M., Stockmeier, C. A. & Albert, P. R. 2009 Human freud-2/CC2D1B: a novel repressor of postsynaptic serotonin-1A receptor expression. *Biol. Psychiatry* **66**, 214–222. (doi:10.1016/j.biopsych.2009.02.033)
- 80 Rogaeva, A. & Albert, P. R. 2007 The mental retardation gene CC2D1A/Freud-1 encodes a long isoform that binds conserved DNA elements to repress gene transcription. *Eur. J. Neurosci.* **26**, 965–974. (doi:10.1111/j.1460-9568.2007.05727.x)
- 81 Hadjighassem, M. R., Galaraga, K. & Albert, P. R. 2011 Freud-2/CC2D1B mediates dual repression of the serotonin-1A receptor gene. *Eur. J. Neurosci.* **33**, 214–223. (doi:10.1111/j.1460-9568.2010.07498.x)
- 82 Lemonde, S. *et al.* 2003 Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. *J. Neuroscience* **23**, 8788–8799.
- 83 Jacobsen, K. X., Vanderluit, J., Slack, R. S. & Albert, P. R. 2008 HES1 regulates 5-HT<sub>1A</sub> receptor gene transcription at a functional polymorphism: essential role in developmental expression. *Mol. Cell. Neurosci.* **38**, 349–358. (doi:10.1016/j.mcn.2008.03.007)
- 84 Kageyama, R., Ohtsuka, T., Hatakeyama, J. & Ohsawa, R. 2005 Roles of bHLH genes in neural stem cell differentiation. *Exp. Cell Res.* **306**, 343–348. (doi:10.1016/j.yexcr.2005.03.015)
- 85 Czesak, M., Le Francois, B., Millar, A. M., Deria, M., Daigle, M., Visvader, J. E., Anisman, H. & Albert, P. R. 2012 Increased serotonin-1A (5-HT<sub>1A</sub>) autoreceptor expression and reduced raphe regulatory Factor-1 (Deaf-1) gene knock-out mice. *J. Biol. Chem.* **287**, 6615–6627. (doi:10.1074/jbc.M111.293027)
- 86 Goswami, D. B., May, W. L., Stockmeier, C. A. & Austin, M. C. 2010 Transcriptional expression of serotonergic regulators in laser-captured microdissected dorsal raphe neurons of subjects with major depressive disorder: sex-specific differences. *J. Neurochem.* **112**, 397–409. (doi:10.1111/j.1471-4159.2009.06462.x)
- 87 Chalmers, D. T., Lopez, J. F., Vazquez, D. M., Akil, H. & Watson, S. J. 1994 Regulation of hippocampal 5-HT<sub>1A</sub> receptor gene expression by dexamethasone. *Neuropsychopharmacology* **10**, 215–222.
- 88 Zhong, P. & Ciaranello, R. D. 1995 Transcriptional regulation of hippocampal 5-HT<sub>1A</sub> receptors by corticosteroid hormones. *Brain Res. Mol. Brain Res.* **29**, 23–34. (doi:10.1016/0169-328X(94)00225-4)
- 89 Ou, X. M., Storrington, J. M., Kushwaha, N. & Albert, P. R. 2001 Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT<sub>1A</sub> receptor gene. *J. Biol. Chem.* **276**, 14 299–14 307. (doi:10.1074/jbc.M005363200)
- 90 Neumaier, J. F., Sexton, T. J., Hamblin, M. W. & Beck, S. G. 2000 Corticosteroids regulate 5-HT<sub>1A</sub> but not 5-HT<sub>1B</sub> receptor mRNA in rat hippocampus. *Brain Res. Mol. Brain Res.* **82**, 65–73. (doi:10.1016/S0169-328X(00)00181-9)
- 91 Meijer, O. C. & de Kloet, E. R. 1995 A role for the mineralocorticoid receptor in a rapid and transient suppression of hippocampal 5-HT<sub>1A</sub> receptor mRNA by corticosterone. *J. Neuroendocrinol.* **7**, 653–657. (doi:10.1111/j.1365-2826.1995.tb00804.x)
- 92 Meijer, O. C., Cole, T. J., Schmid, W., Schutz, G., Joels, M. & De Kloet, E. R. 1997 Regulation of hippocampal 5-HT<sub>1A</sub> receptor mRNA and binding in transgenic mice with a targeted disruption of the glucocorticoid receptor. *Brain Res. Mol. Brain Res.* **46**, 290–296. (doi:10.1016/S0169-328X(97)00002-8)
- 93 Lanzenberger, R. *et al.* 2010 Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. *Int. J. Neuropsychopharmacol.* **13**, 1129–1143. (doi:10.1017/S1461145710000581)
- 94 Froger, N. *et al.* 2004 Neurochemical and behavioral alterations in glucocorticoid receptor-impaired transgenic mice after chronic mild stress. *J. Neurosci.* **24**, 2787–2796. (doi:10.1523/JNEUROSCI.4132-03.2004)
- 95 Evvard, A., Barden, N., Hamon, M. & Adrien, J. 2006 Glucocorticoid receptor-dependent desensitization of 5-HT<sub>1A</sub> autoreceptors by sleep deprivation: studies in GR-1 transgenic mice. *Sleep* **29**, 31–36.
- 96 Meijer, O. C. & de Kloet, E. R. 1998 Corticosterone and serotonergic neurotransmission in the hippocampus: functional implications of central corticosteroid receptor diversity. *Crit. Rev. Neurobiol.* **12**, 1–20.
- 97 Wei, Q. *et al.* 2004 Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. *Proc. Natl Acad. Sci. USA* **101**, 11 851–11 856. (doi:10.1073/pnas.0402208101)
- 98 Rozeboom, A. M., Akil, H. & Seasholtz, A. F. 2007 Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. *Proc. Natl Acad. Sci. USA* **104**, 4688–4693. (doi:10.1073/pnas.0606067104)
- 99 Stockmeier, C. A., Shapiro, L. A., Dilley, G. E., Kolli, T. N., Friedman, L. & Rajkowska, G. 1998 Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. *J. Neurosci.* **18**, 7394–7401.
- 100 Boldrini, M., Underwood, M. D., Mann, J. J. & Arango, V. 2008 Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. *J. Psychiatry Res.* **42**, 433–442. (doi:10.1016/j.jpsychires.2007.05.004)
- 101 Parsey, R. V. *et al.* 2010 Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. *Biol. Psychiatry* **68**, 170–178. (doi:10.1016/j.biopsych.2010.03.023)
- 102 Parsey, R. V., Olvet, D. M., Oquendo, M. A., Huang, Y. Y., Ogden, R. T. & Mann, J. J. 2006 Higher 5-HT<sub>1A</sub> receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. *Neuropsychopharmacology* **31**, 1745–1749. (doi:10.1038/sj.npp.1300992)
- 103 Miller, J. M., Brennan, K. G., Ogden, T. R., Oquendo, M. A., Sullivan, G. M., Mann, J. J. & Parsey, R. V. 2009

- Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. *Neuropsychopharmacology* **34**, 2275–2284. (doi:10.1038/npp.2009.54)
- 104 Sullivan, G. M., Ogden, R. T., Oquendo, M. A., Kumar, J. S., Simpson, N., Huang, Y. Y., Mann, J. J. & Parsey, R. V. 2009 Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. *Biol. Psychiatry* **66**, 223–230. (doi:10.1016/j.biopsych.2009.01.028)
  - 105 Stockmeier, C. A. 2003 Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. *J. Psychiatry Res.* **37**, 357–373. (doi:10.1016/S0022-3956(03)00050-5)
  - 106 Stockmeier, C. A., Howley, E., Shi, X., Sobanska, A., Clarke, G., Friedman, L. & Rajkowska, G. 2009 Antagonist but not agonist labeling of serotonin-1A receptors is decreased in major depressive disorder. *J. Psychiatry Res.* **43**, 887–894. (doi:10.1016/j.jpsychires.2009.01.001)
  - 107 Anisman, H., Du, L., Palkovits, M., Faludi, G., Kovacs, G. G., Szontagh-Kishazi, P., Merali, Z. & Poulter, M. O. 2008 Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. *J. Psychiatry Neurosci.* **33**, 131–141.
  - 108 Underwood, M. D., Kassir, S. A., Bakalian, M. J., Galfalvy, H., Mann, J. J. & Arango, V. 2011 Neuron density and serotonin receptor binding in prefrontal cortex in suicide. *Int. J. Neuropsychopharmacol.* **15**, 435–447. (doi:10.1017/s1461145711000691)
  - 109 Savitz, J., Lucki, I. & Drevets, W. C. 2009 5-HT(1A) receptor function in major depressive disorder. *Prog. Neurobiol.* **88**, 17–31. (doi:10.1016/j.pneurobio.2009.01.009)
  - 110 Sargent, P. A., Kjaer, K. H., Bench, C. J., Rabiner, E. A., Messa, C., Meyer, J., Gunn, R. N., Grasby, P. M. & Cowen, P. J. 2000 Brain serotonin<sub>1A</sub> receptor binding measured by positron emission tomography with [<sup>11</sup>C]WAY-100635: effects of depression and antidepressant treatment. *Arch. Gen. Psychiatry* **57**, 174–180. (doi:10.1001/archpsyc.57.2.174)
  - 111 Bhagwagar, Z., Rabiner, E. A., Sargent, P. A., Grasby, P. M. & Cowen, P. J. 2004 Persistent reduction in brain serotonin<sub>1A</sub> receptor binding in recovered depressed men measured by positron emission tomography with [<sup>11</sup>C]WAY-100635. *Mol. Psychiatry* **9**, 386–392. (doi:10.1038/sj.mp.4001401)
  - 112 Cleare, A. J., Messa, C., Rabiner, E. A. & Grasby, P. M. 2005 Brain 5-HT<sub>1A</sub> receptor binding in chronic fatigue syndrome measured using positron emission tomography and [<sup>11</sup>C]WAY-100635. *Biol. Psychiatry* **57**, 239–246. (doi:10.1016/j.biopsych.2004.10.031)
  - 113 Hirvonen, J., Karlsson, H., Kajander, J., Lepola, A., Markkula, J., Rasi-Hakala, H., Nagren, K., Salminen, J. K. & Hietala, J. 2008 Decreased brain serotonin 5-HT<sub>1A</sub> receptor availability in medication-naïve patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-<sup>11</sup>C]WAY-100635. *Int. J. Neuropsychopharmacol.* **11**, 465–476. (doi:10.1017/S1461145707008140)
  - 114 Neumeister, A. *et al.* 2004 Reduced serotonin type 1A receptor binding in panic disorder. *J. Neurosci.* **24**, 589–591. (doi:10.1523/JNEUROSCI.4921-03.2004)
  - 115 Nash, J. R., Sargent, P. A., Rabiner, E. A., Hood, S. D., Argyropoulos, S. V., Potokar, J. P., Grasby, P. M. & Nutt, D. J. 2008 Serotonin 5-HT<sub>1A</sub> receptor binding in people with panic disorder: positron emission tomography study. *Br. J. Psychiatry* **193**, 229–234. (doi:10.1192/bjp.bp.107.041186)
  - 116 Lanzenberger, R. R. *et al.* 2007 Reduced serotonin-1A receptor binding in social anxiety disorder. *Biol. Psychiatry* **61**, 1081–1089. (doi:10.1016/j.biopsych.2006.05.022)
  - 117 Tauscher, J., Bagby, R. M., Javanmard, M., Christensen, B. K., Kasper, S. & Kapur, S. 2001 Inverse relationship between serotonin 5-HT(1A) receptor binding and anxiety: a [(11)C]WAY-100635 PET investigation in healthy volunteers. *Am. J. Psychiatry* **158**, 1326–1328. (doi:10.1176/appi.ajp.158.8.1326)
  - 118 Sullivan, G. M., Oquendo, M. A., Simpson, N., Van Heertum, R. L., Mann, J. J. & Parsey, R. V. 2005 Brain serotonin 1A receptor binding in major depression is related to psychic and somatic anxiety. *Biol. Psychiatry* **58**, 947–954. (doi:10.1016/j.biopsych.2005.05.006)
  - 119 Hesselgrave, N. & Parsey, R. V. In press. Imaging the serotonin 1A receptor using [<sup>11</sup>C]WAY100635 in healthy controls and major depression. *Phil. Trans. R. Soc. B.*
  - 120 Hume, S., Hirani, E., Opacka-Juffry, J., Myers, R., Townsend, C., Pike, V. & Grasby, P. 2001 Effect of 5-HT on binding of [(11)C] WAY 100635 to 5-HT(1A) receptors in rat brain, assessed using *in vivo* microdialysis and PET after fenfluramine. *Synapse* **41**, 150–159. (10.1002/syn.1069)
  - 121 Udo de Haes, J. I., Cremers, T. I., Bosker, F. J., Postema, F., Tiemersma-Wegman, T. D. & den Boer, J. A. 2005 Effect of increased serotonin levels on [18F]MPPF binding in rat brain: fenfluramine versus the combination of citalopram and ketanserin. *Neuropsychopharmacology* **30**, 1624–1631. (10.1038/sj.npp.1300721)
  - 122 Milak, M. S., Severance, A. J., Ogden, R. T., Prabhakaran, J., Kumar, J. S., Majo, V. J., Mann, J. J. & Parsey, R. V. 2008 Modeling considerations for [<sup>11</sup>C]-CUMI-101, an agonist radiotracer for imaging serotonin 1A receptor *in vivo* with PET. *J. Nucl. Med.* **49**, 587–596. (doi:10.2967/jnumed.107.046540)
  - 123 Fisher, P. M., Meltzer, C. C., Ziolkowski, S. K., Price, J. C., Moses-Kolko, E. L., Berga, S. L. & Hariri, A. R. 2006 Capacity for 5-HT<sub>1A</sub>-mediated autoregulation predicts amygdala reactivity. *Nat. Neurosci.* **9**, 1362–1363. (doi:10.1038/nn1780)
  - 124 Jovanovic, H., Perski, A., Berglund, H. & Savic, I. 2011 Chronic stress is linked to 5-HT(1A) receptor changes and functional disintegration of the limbic networks. *Neuroimage* **55**, 1178–1188. (doi:10.1016/j.neuroimage.2010.12.060)
  - 125 Stiedl, O., Misane, I., Spiess, J. & Ogren, S. O. 2000 Involvement of the 5-HT<sub>1A</sub> receptors in classical fear conditioning in C57BL/6J mice. *J. Neurosci.* **20**, 8515–8527.
  - 126 Spindelegger, C. *et al.* 2009 Influence of escitalopram treatment on 5-HT(1A) receptor binding in limbic regions in patients with anxiety disorders. *Mol. Psychiatry* **14**, 1040–1050. (doi:10.1038/mp.2008.35)
  - 127 Rabiner, E. A., Gunn, R. N., Wilkins, M. R., Sargent, P. A., Mocaer, E., Sedman, E., Cowen, P. J. & Grasby, P. M. 2000 Drug action at the 5-HT(1A) receptor *in vivo*: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. *Nucl. Med. Biol.* **27**, 509–513. (doi:10.1016/S0969-8051(00)00120-7)
  - 128 Hirani, E., Opacka-Juffry, J., Gunn, R., Khan, I., Sharp, T. & Hume, S. 2000 Pindolol occupancy of 5-HT(1A) receptors measured *in vivo* using small animal positron emission tomography with carbon-11 labeled WAY 100635. *Synapse* **36**, 330–341. (doi:10.1002/(SICI)1098-2396(20000615)36:4<330::AID-SYN10>3.0.CO;2-H)
  - 129 Blier, P. & Ward, N. M. 2003 Is there a role for 5-HT(1A) agonists in the treatment of depression?



- Biol. Psychiatry* **53**, 193–203. (doi:10.1016/S0006-3223(02)01643-8)
- 130 Trivedi, M. H. *et al.* 2006 Medication augmentation after the failure of SSRIs for depression. *N. Engl. J. Med.* **354**, 1243–1252. (doi:10.1056/NEJMoa052964)
  - 131 Llado-Pelfort, L., Assie, M. B., Newman-Tancredi, A., Artigas, F. & Celada, P. 2010 Preferential *in vivo* action of F15599, a novel 5-HT<sub>1A</sub> receptor agonist, at post-synaptic 5-HT<sub>1A</sub> receptors. *Br. J. Pharmacol.* **160**, 1929–1940. (10.1111/j.1476-5381.2010.00738.x)
  - 132 Jacobsen, J. P., Siesser, W. B., Sachs, B. D., Peterson, S., Cools, M. J., Setola, V., Folgering, J. H., Flik, G. & Caron, M. G. 2012 Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice. *Mol. Psychiatry* **12**, 694–704. (doi:10.1038/mp.2011.50)
  - 133 Kiyasova, V., Fernandez, S. P., Laine, J., Stankovski, L., Muzerelle, A., Doly, S. & Gaspar, P. 2011 A genetically defined morphologically and functionally unique subset of 5-HT neurons in the mouse raphe nuclei. *J. Neurosci.* **31**, 2756–2768. (doi:10.1523/jneurosci.4080-10.2011)
  - 134 Czesak, M., Lemonde, S., Peterson, E. A., Rogaeva, A. & Albert, P. R. 2006 Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. *J. Neurosci.* **26**, 1864–1871. (doi:10.1523/JNEUROSCI.2643-05.2006)
  - 135 Lothe, A., Boni, C., Costes, N., Bouvard, S., Gorwood, P., Lavenne, F., Alvarez, M. & Ryvlin, P. 2010 5-HT<sub>1A</sub> gene promoter polymorphism and [18F]MPPF binding potential in healthy subjects: a PET study. *Behav. Brain Funct.* **6**, 37. (doi:10.1186/1744-9081-6-37)
  - 136 David, S. P., Murthy, N. V., Rabiner, E. A., Munafo, M. R., Johnstone, E. C., Jacob, R., Walton, R. T. & Grasby, P. M. 2005 A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT<sub>1A</sub> receptor binding in humans. *J. Neurosci.* **25**, 2586–2590. (doi:10.1523/JNEUROSCI.3769-04.2005)
  - 137 Lundberg, J., Borg, J., Halldin, C. & Farde, L. 2007 A PET study on regional coexpression of 5-HT<sub>1A</sub> receptors and 5-HTT in the human brain. *Psychopharmacology (Berl.)* **195**, 425–433. (doi:10.1007/s00213-007-0928-3)
  - 138 Lothe, A., Boni, C., Costes, N., Gorwood, P., Bouvard, S., Le Bars, D., Lavenne, F. & Ryvlin, P. 2009 Association between triallelic polymorphism of the serotonin transporter and [18F]MPPF binding potential at 5-HT<sub>1A</sub> receptors in healthy subjects. *Neuroimage* **47**, 482–492. (doi:10.1016/j.neuroimage.2009.04.067)
  - 139 Arango, V., Underwood, M. D., Gubbi, A. V. & Mann, J. J. 1995 Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. *Brain Res.* **688**, 121–133. (doi:10.1016/0006-8993(95)00523-S)
  - 140 Moses-Kolko, E. L. *et al.* 2007 Measurement of 5-HT<sub>1A</sub> receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. *Synapse* **61**, 523–530. (doi:10.1002/syn.20398)
  - 141 Hahn, A., Lanzemberger, R., Wadsak, W., Spindelegger, C., Moser, U., Mien, L. K., Mitterhauser, M. & Kasper, S. 2010 Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. *J. Neurosci.* **30**, 14 482–14 489. (doi:10.1523/JNEUROSCI.2409-10.2010)
  - 142 Jovanovic, H., Cerin, A., Karlsson, P., Lundberg, J., Halldin, C. & Nordstrom, A. L. 2006 A PET study of 5-HT<sub>1A</sub> receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. *Psychiatry Res.* **148**, 185–193. (doi:10.1016/j.psychres.2006.05.002)
  - 143 Le François, B., Czesak, M., Steubl, D. & Albert, P. R. 2008 Transcriptional regulation at a HTR1A polymorphism associated with mental illness. *Neuropharmacology* **55**, 977–985. (doi:10.1016/j.neuropharm.2008.06.046)
  - 144 Kishi, T. *et al.* 2009 Serotonin 1A receptor gene and major depressive disorder: an association study and meta-analysis. *J. Hum. Genet.* **54**, 629–633. (doi:10.1038/jhg.2009.84)
  - 145 Neff, C. D. *et al.* 2009 Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression. *Mol. Psychiatry* **14**, 621–630. (doi:10.1038/mp.2008.8)
  - 146 Anttila, S., Huuhka, K., Huuhka, M., Rontu, R., Hurme, M., Leinonen, E. & Lehtimäki, T. 2007 Interaction between 5-HT<sub>1A</sub> and BDNF genotypes increases the risk of treatment-resistant depression. *J. Neural Transm.* **114**, 1065–1068. (doi:10.1007/s00702-007-0705-9)
  - 147 Kishi, T. *et al.* 2011 Serotonin 1A receptor gene, schizophrenia and bipolar disorder: an association study and meta-analysis. *Psychiatry Res.* **185**, 20–26. (doi:10.1016/j.psychres.2010.06.003)
  - 148 Kim, H. K., Kim, S. J., Lee, Y. J., Lee, H. J., Kang, S. G., Choi, J. E., Yun, K. W. & Lim, W. J. 2011 Influence of the interaction between the serotonin 1A receptor C-1019G polymorphism and negative life stressors on the development of depression. *Neuropsychobiology* **64**, 1–8. (doi:10.1159/000322144)
  - 149 Choi, W. S., Lee, B. H., Yang, J. C. & Kim, Y. K. 2010 Association study between 5-HT<sub>1A</sub> receptor gene C(-1019)G polymorphism and panic disorder in a Korean population. *Psychiatry Invest.* **7**, 141–146. (doi:10.4306/pi.2010.7.2.141)
  - 150 Molina, E., Cervilla, J., Rivera, M., Torres, F., Bellon, J. A., Moreno, B., King, M., Nazareth, I. & Gutierrez, B. 2011 Polymorphic variation at the serotonin 1-A receptor gene is associated with comorbid depression and generalized anxiety. *Psychiatry Genet.* **21**, 195–201. (doi:10.1097/YPG.0b013e3283457a48)
  - 151 Schmitz, A., Kirsch, P., Reuter, M., Alexander, N., Kozys, E., Kuepper, Y., Osinsky, R. & Hennig, J. 2009 The 5-HT<sub>1A</sub> C(-1019)G polymorphism, personality and electrodermal reactivity in a reward/punishment paradigm. *Int. J. Neuropsychopharmacol.* **12**, 383–392. (doi:10.1017/S1461145708009401)
  - 152 Blaya, C., Salum, G. A., Moorjani, P., Segnifredo, A. C., Heldt, E., Leistner-Segal, S., Smoller, J. W. & Manfro, G. G. 2011 Panic disorder and serotonergic genes (SLC6A4, HTR1A and HTR2A): association and interaction with childhood trauma and parenting. *Neurosci. Lett.* **485**, 11–15. (doi:10.1016/j.neulet.2010.08.042)
  - 153 Lim, S. W., Ha, J., Shin, D. W., Woo, H. Y. & Kim, K. H. 2010 Associations between the serotonin-1A receptor C(-1019)G polymorphism and disordered eating symptoms in female adolescents. *J. Neural Transm.* **117**, 773–779. (doi:10.1007/s00702-010-0412-9)
  - 154 Lee, Y. S., Choi, S. W., Han, D. H., Kim, D. J. & Joe, K. H. 2009 Clinical manifestation of alcohol withdrawal symptoms related to genetic polymorphisms of two serotonin receptors and serotonin transporter. *Eur. Addict. Res.* **15**, 39–46. (doi:10.1159/000173008)
  - 155 Videtic, A., Zupanc, T., Pregelj, P., Balazic, J., Tomori, M. & Komel, R. 2009 Suicide, stress and serotonin receptor 1A promoter polymorphism -1019C>G in Slovenian suicide victims. *Eur. Arch. Psychiatry Clin. Neurosci.* **259**, 234–238. (doi:10.1007/s00406-008-0861-4)
  - 156 Fakra, E. *et al.* 2009 Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. *Arch. Gen. Psychiatry* **66**, 33–40. (doi:10.1001/archpsyc.66.1.33)

- 157 Domschke, K. *et al.* 2006 Association of the functional -1019C/G 5-HT<sub>1A</sub> polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. *Int. J. Neuropsychopharmacol.* **9**, 349–355. (doi:10.1017/S1461145705005869)
- 158 Dannlowski, U. *et al.* 2007 Serotonergic genes modulate amygdala activity in major depression. *Genes Brain Behav.* **6**, 672–676. (doi:10.1111/j.1601-183X.2006.00297.x)
- 159 Beste, C., Domschke, K., Falkenstein, M. & Konrad, C. 2010 Differential modulations of response control processes by 5-HT<sub>1A</sub> gene variation. *Neuroimage* **50**, 764–771. (doi:10.1016/j.neuroimage.2009.11.067)
- 160 Beste, C., Domschke, K., Kolev, V., Yordanova, J., Baffa, A., Falkenstein, M. & Konrad, C. 2010 Functional 5-HT<sub>1A</sub> receptor polymorphism selectively modulates error-specific subprocesses of performance monitoring. *Hum. Brain Mapp.* **31**, 621–630.
- 161 Beste, C., Domschke, K., Radenz, B., Falkenstein, M. & Konrad, C. 2011 The functional 5-HT<sub>1A</sub> receptor polymorphism affects response inhibition processes in a context-dependent manner. *Neuropsychologia* **49**, 2664–2672. (doi:10.1016/j.neuropsychologia.2011.05.014)
- 162 Beste, C., Heil, M., Domschke, K. & Konrad, C. 2010 The relevance of the functional 5-HT<sub>1A</sub> receptor polymorphism for attention and working memory processes during mental rotation of characters. *Neuropsychologia* **48**, 1248–1254. (doi:10.1016/j.neuropsychologia.2009.12.025)
- 163 Serretti, A., Artioli, P., Lorenzi, C., Pirovano, A., Tubazio, V. & Zanardi, R. 2004 The C(-1019)G polymorphism of the 5-HT<sub>1A</sub> gene promoter and antidepressant response in mood disorders: preliminary findings. *Int. J. Neuropsychopharmacol.* **7**, 453–460. (doi:10.1017/S1461145704004687)
- 164 Yevtushenko, O. O., Oros, M. M. & Reynolds, G. P. 2010 Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT<sub>1A</sub> receptor gene polymorphism. *J. Affect. Disord.* **123**, 308–311. (doi:10.1016/j.jad.2009.09.007)
- 165 Lemonde, S., Du, L., Bakish, D., Hrdina, P. & Albert, P. R. 2004 Association of the C(-1019)G 5-HT<sub>1A</sub> functional promoter polymorphism with antidepressant response. *Int. J. Neuropsychopharmacol.* **7**, 501–506. (doi:10.1017/S1461145704004699)
- 166 Kato, M. *et al.* 2009 Effect of 5-HT<sub>1A</sub> gene polymorphisms on antidepressant response in major depressive disorder. *Am. J. Med. Genet. B. Neuropsychiatry Genet.* **150B**, 115–123. (doi:10.1002/ajmg.b.30783)
- 167 Villafuerte, S. M., Vallabhaneni, K., Sliwerska, E., McMahon, F. J., Young, E. A. & Burmeister, M. 2009 SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. *Psychiatry Genet.* **19**, 281–291. (doi:10.1097/YPG.0b013e32832a506e)
- 168 Reynolds, G. P., Arranz, B., Templeman, L. A., Furtuzinhos, S. & San, L. 2006 Effect of 5-HT<sub>1A</sub> receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naïve psychotic patients. *Am. J. Psychiatry* **163**, 1826–1829. (doi:10.1176/appi.ajp.163.10.1826)
- 169 Wang, L., Fang, C., Zhang, A., Du, J., Yu, L., Ma, J., Feng, G., Xing, Q. & He, L. 2008 The -1019 C/G polymorphism of the 5-HT<sub>1A</sub> receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. *J. Psychopharmacol.* **22**, 904–909. (doi:10.1177/0269881107081522)
- 170 Chipman, P., Jorm, A. F., Tan, X. Y. & Easteal, S. 2010 No association between the serotonin-1A receptor gene single nucleotide polymorphism rs6295C/G and symptoms of anxiety or depression, and no interaction between the polymorphism and environmental stressors of childhood anxiety or recent stressful life events on anxiety or depression. *Psychiatry Genet.* **20**, 8–13. (doi:10.1097/YPG.0b013e3283351140)
- 171 Koller, G., Bondy, B., Preuss, U. W., Zill, P. & Soyka, M. 2006 The C(-1019)G 5-HT<sub>1A</sub> promoter polymorphism and personality traits: no evidence for significant association in alcoholic patients. *Behav. Brain Funct.* **2**, 7. (doi:10.1186/1744-9081-2-7)
- 172 Wasserman, D., Geijer, T., Sokolowski, M., Rozanov, V. & Wasserman, J. 2006 The serotonin 1A receptor C(-1019)G polymorphism in relation to suicide attempt. *Behav. Brain Funct.* **2**, 14. (doi:10.1186/1744-9081-2-14)
- 173 Zetzsche, T. *et al.* 2008 5-HT<sub>1A</sub> receptor gene C -1019 G polymorphism and amygdala volume in borderline personality disorder. *Genes Brain Behav.* **7**, 306–313. (doi:10.1111/j.1601-183X.2007.00353.x)
- 174 Caspi, A. *et al.* 2003 Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science* **301**, 386–389. (doi:10.1126/science.1083968)
- 175 Jacob, C. P. *et al.* 2010 A gene-environment investigation on personality traits in two independent clinical sets of adult patients with personality disorder and attention deficit/hyperactive disorder. *Eur. Arch. Psychiatry Clin. Neurosci.* **260**, 317–326. (doi:10.1007/s00406-009-0079-0)
- 176 Benedetti, F., Radaelli, D., Poletti, S., Locatelli, C., Dallaspezia, S., Lorenzi, C., Pirovano, A., Colombo, C. & Smeraldi, E. 2011 Association of the C(-1019)G 5-HT<sub>1A</sub> promoter polymorphism with exposure to stressors preceding hospitalization for bipolar depression. *J. Affect. Disord.* **132**, 297–300. (doi:10.1016/j.jad.2011.02.024)
- 177 Vicentic, A., Francis, D., Moffett, M., Lakatos, A., Rogge, G., Hubert, G. W., Harley, J. & Kuhar, M. J. 2006 Maternal separation alters serotonergic transporter densities and serotonergic 1A receptors in rat brain. *Neuroscience* **140**, 355–365. (doi:10.1016/j.neuroscience.2006.02.008)
- 178 Law, A. J., Pei, Q., Feldon, J., Pryce, C. R. & Harrison, P. J. 2009 Gene expression in the anterior cingulate cortex and amygdala of adolescent marmoset monkeys following parental separations in infancy. *Int. J. Neuropsychopharmacol.* **12**, 761–772. (doi:10.1017/S1461145708009723)
- 179 Goodfellow, N. M., Benekareddy, M., Vaidya, V. A. & Lamb, E. K. 2009 Layer II/III of the prefrontal cortex: inhibition by the serotonin 5-HT<sub>1A</sub> receptor in development and stress. *J. Neurosci.* **29**, 10 094–10 103. (doi:10.1523/JNEUROSCI.1960-09.2009)
- 180 Armbruster, D., Mueller, A., Strobel, A., Lesch, K. P., Brocke, B. & Kirschbaum, C. 2011 Predicting cortisol stress responses in older individuals: influence of serotonin receptor 1A gene (HTR1A) and stressful life events. *Horm. Behav.* **60**, 105–111. (doi:10.1016/j.yhbeh.2011.03.010)
- 181 Birmingham, D. J. *et al.* 2006 Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A -1019 G allele. *Arthritis Rheum.* **54**, 3291–3299. (doi:10.1002/art.22135)
- 182 Southwick, S. M., Vythilingam, M. & Charney, D. S. 2005 The psychobiology of depression and resilience to stress: implications for prevention and treatment. *Annu. Rev. Clin. Psychol.* **1**, 255–291. (doi:10.1146/annurev.clinpsy.1.102803.143948)

- 183 Bosker, F. J. *et al.* 2011 Poor replication of candidate genes for major depressive disorder using genome-wide association data. *Mol. Psychiatry* **16**, 516–532. (doi:10.1038/mp.2010.38)
- 184 Dhingra, V., Magnay, J. L., O'Brien, P. M., Chapman, G., Fryer, A. A. & Ismail, K. M. 2007 Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. *Obstet. Gynecol.* **110**, 788–792. (doi:10.1097/01.AOG.0000284448.73490.ac)
- 185 Shim, S. H., Hwangbo, Y., Kwon, Y. J., Jeong, H. Y., Lee, B. H., Hwang, J. A. & Kim, Y. K. 2010 A case-control association study of serotonin 1A receptor gene and tryptophan hydroxylase 2 gene in attention deficit hyperactivity disorder. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **34**, 974–979. (doi:10.1016/j.pnpbp.2010.05.006)
- 186 Cox, R. F., Meller, E. & Waszczak, B. L. 1993 Electrophysiological evidence for a large receptor reserve for inhibition of dorsal raphe neuronal firing by 5-HT<sub>1A</sub> agonists. *Synapse* **14**, 297–304. (doi:10.1002/syn.890140407)
- 187 Valdizan, E. M., Castro, E. & Pazos, A. 2010 Agonist-dependent modulation of G-protein coupling and transduction of 5-HT<sub>1A</sub> receptors in rat dorsal raphe nucleus. *Int. J. Neuropsychopharmacol.* **13**, 835–843. (doi:10.1017/S1461145709990940)
- 188 Mannoury la Cour, C., El Mestikawy, S., Hanoun, N., Hamon, M. & Lanfumey, L. 2006 Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. *Mol. Pharmacol.* **70**, 1013–1021. (doi:10.1124/mol.106.022756)
- 189 Newman-Tancredi, A., Cussac, D., Marini, L. & Millan, M. J. 2002 Antibody capture assay reveals bell-shaped concentration-response isotherms for H5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. *Mol. Pharmacol.* **62**, 590–601. (doi:10.1124/mol.62.3.590)